Key highlights:
London, UK, 2 November 2017: dorsaVi (ASX: DVL) today announced the commercial launch of the revolutionary movement analysis product ViMove2™ in the United Kingdom and European markets, with the first set of pre-orders shipping today to clients. The launch of ViMove2™ has been embraced by running specialists and personal trainers, as it marries ease of use with high quality data, to aid their clients and their business. They join physiotherapists, osteopaths, chiropractors and podiatrists in the region already using the existing ViMove technology.
ViMove2™ consists of small and easy-to-use sensors which measure and monitor movement. Combined with its simplified software interface and lower entry sale price, ViMove2™ allows a broad range of customers to assess running gait, knee control and low back movement patterns with clinical accuracy. The low price point of £999 for the hardware, and an ongoing fee for the software license (£99 or £179 monthly) means running coaches, trainers and gyms can now access this technology.
“Using ViMove has been like switching the lights on, and it’s my clients who benefit, whether they are elite runners, weekend warriors, or park runners,” said Shane Benzie, running technique coach and movement specialist and founder of Running Reborn.
dorsaVi Chief Executive Officer Andrew Ronchi said: “As leaders in innovative movement technology, dorsaVi is excited to introduce a highly intuitive product like ViMove2™ to a wide range of clients who want to better understand and assess running movement. We’ve positioned ViMove2™ at an attractive price point to create equal access for trainers, coaches, physiotherapists, osteopaths, chiropractors and podiatrists alike.”
ViMove2™ is available in the UK via dorsaVi's webstore: www.dorsavi.com/uk/en/vimove
Watch the ViMove2™ overview video here: http://get.dorsavi.com/vimove2/
Request more information about ViMove2
Randomised Controlled Trial with dorsaVi technology finds back pain patients monitored and treated using dorsaVi's sensors had significant, sustained improvements in pain and function.
Recent news: What's happening at dorsaVi
ViPerform and the NFL: How Loren Landow uses objective data to assess risk of injury